Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

BioCardia, Inc. Common Stock

BCDA

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.765 – $0.811
Volume 27,897
Market cap $12M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$11.96M
Price / earnings
—
Price / book
14.32×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.26×

Profitability

Earnings per share
-$0.51
Return on assets
-249.85%
Return on equity
-918.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.11×
Quick ratio
1.11×
Cash ratio
1.06×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.62M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BCDA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$600K$730K$1.03M$885K$552K$683K$1.2M$906K
Research and development$1.24M$893K$1.24M$1.13M$936K$1.37M$1.53M$1.42M
Total operating expenses$1.84M$1.62M$2.27M$2.01M$1.49M$2.05M$2.73M$2.32M
Operating income-$1.84M-$1.62M-$2.27M-$2.01M-$1.49M-$2.05M-$2.73M-$2.32M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.82M-$1.61M-$2.26M-$1.98M-$1.48M-$2.05M-$2.71M-$2.3M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.82M-$1.61M-$2.26M-$1.98M-$1.48M-$2.05M-$2.71M-$2.3M
Net income attributable to common shareholders-$1.82M-$1.61M-$2.26M-$1.98M-$1.48M-$2.05M-$2.71M-$2.3M
EBITDA-$1.83M-$1.62M-$2.26M-$2.01M-$1.48M-$2.05M-$2.71M-$2.31M
Basic earnings per share-$0.12-$0.13-$0.21-$0.19-$0.24-$0.40-$0.59-$0.50
Diluted earnings per share-$0.12-$0.13-$0.21-$0.19-$0.24-$0.40-$0.59-$0.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

BioCardia announced the presentation of its CardiAMP HF II trial design at the HFSA Annual Scientific Meeting. The trial evaluates high-dose autologous cell therapy for patients with ischemic heart failure with reduced ejection fraction. The FDA has granted category B designation for the CardiAMP system and agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval. BioCardia is advancing regulatory submissions with the FDA and Japan's PMDA.

GlobeNewswire Inc.

BioCardia Announces $4.4 Million Financing

BioCardia completed a capital raise of 3.5 million shares at $1.279 per share, extending cash runway into Q1 2027 and potentially beyond PMDA approval. The company received FDA confirmation that CardiAMP HF II trial may support premarket approval, and obtained Japan PMDA Record of Advice supporting regulatory submission for CardiAMP cell therapy for ischemic heart failure treatment.

GlobeNewswire Inc.

BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

BioCardia announced that the FDA identified two regulatory pathways for its Helix Transendocardial Delivery Catheter System, with the FDA's preferred route being simultaneous approval with the CardiAMP cell therapy system. The FDA raised no concerns regarding Helix safety data, device performance, or agent compatibility. An alternative DeNovo pathway was also suggested as a potential route to independent Helix market clearance.

GlobeNewswire Inc.

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, a minimally invasive device for intramyocardial therapeutic and diagnostic agent delivery. The FDA's Center for Devices and Radiological Health (CDRH) will lead the review in consultation with the Center for Biological Evaluation and Research (CBER). The company expects this approval to support its CardiAMP Cell Therapy program for treating ischemic heart failure.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 30, 20241-for-15reverse split
Jun 6, 20191-for-9reverse split
Nov 3, 20171-for-12reverse split
Jan 6, 20046-for-1forward split